US Budget Impact Model for Selinexor in Relapsed or Refractory Multiple Myeloma
Jan Bassali, 1 Ian Gopal Gould, 2 James A Kaye, 3 Deirdre Mladsi, 4 Jyotsna Mehta 5 1Global Medical and Scientific Affairs Department , Karyopharm Therapeutics, Newton, MA, 02459, USA; 2Research Health Economy, RTI Health Solutions, Research Triangle Park, NC 27709-2194, USA; 3Epidemiology, RTI Heal...
Saved in:
Main Authors: | Bassali J (Author), Gould IG (Author), Kaye JA (Author), Mladsi D (Author), Mehta J (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma
by: Dolph M, et al.
Published: (2021) -
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
by: Joseph NS, et al.
Published: (2021) -
Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States
by: Shah A, et al.
Published: (2021) -
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
by: José-Ángel Her, et al.
Published: (2022) -
Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
by: Sonia Morè, et al.
Published: (2020)